{
  "id": 1022936,
  "title": "Are Wall Street Analysts Bullish on Solventum Stock?",
  "url": "https://urgent.news/2026/08/14/are-wall-street-analysts-bullish-on-solventum-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-14T10:07:47.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-bullish-solventum-100747769.html"
  },
  "original_language": "en",
  "account": "Wall Street analysts are currently divided on whether to be bullish on Solventum Corporation's (SOLV) stock. With a market capitalization of approximately $14.5 billion, the Minnesota-based company develops healthcare solutions through health, material, and data science. While SOLV has underperformed the broader market and the S&P 500 Index over the past year, it has outperformed both on a year-to-date basis. In their latest Q2 FY2026 earnings report, SOLV reported a 2.2% year-over-year increase in net sales and a 9.5% increase in organic sales. The company raised its full-year growth guidance and adjusted EPS expectations, leading to a \"Moderate Buy\" consensus rating from analysts. However, the number of \"Strong Buy\" recommendations has decreased among the 16 analysts covering SOLV stock. Price targets from Wells Fargo's Nathan Treybeck suggest a 7.7% upside potential from SOLV's current share price.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}